정책동향
Beyond borders : Global biotechnology report 2009
- 등록일2009-10-22
- 조회수8862
- 분류정책동향 > 기타 > 기타
-
자료발간일
2009-09-16
-
출처
ERNST&Young
-
원문링크
-
키워드
#Global biotechnology #biotech
- 첨부파일
Beyond_borders_2009.pdf
Beyond borders
Global biotechnology report 2009
Global biotechnology report 2009
Contents
Beyond business as usual? The global perspective
Global section
2 Global introduction
Beyond business as usual?
4 The interconnectedness of all things
How the housing markets sneezed and biotech caught a cold
9 A closer look
Enlightened competition
10 Necessity is the mother of all models
How unprecedented changes are driving new approaches
How unprecedented changes are driving new approaches
18 Survival of the focused
John Martin, Gilead Sciences, Inc.
John Martin, Gilead Sciences, Inc.
19 Innovation from a string of pearls
James M. Cornelius, Bristol-Myers Squibb
James M. Cornelius, Bristol-Myers Squibb
20 Venture capitalists speak out
The more things change, the more they stay the same?
The more things change, the more they stay the same?
22 Valuing innovation: new approaches for new products and changing expectations
Andrew Dillon and Sarah Garner, NICE
24 Global year in review
Turbulent times
Turbulent times
A Darwinian moment? The Americas perspective
Americas section
30 Americas introduction
A Darwinian moment?
37 A closer look
Compensation and benefits in turbulent times
Compensation and benefits in turbulent times
38 CEO roundtable
Only the innovative survive: perspectives from biotech’s next generation
• Jean-Jacques Bienaimé, BioMarin • ioMarin Pharmaceutical Inc.
• Jean-Paul Clozel, Actelion Pharmaceuticals, Ltd
• Colin Goddard, OSI
• Louis Lange, CV Therapeutics
Only the innovative survive: perspectives from biotech’s next generation
• Jean-Jacques Bienaimé, BioMarin • ioMarin Pharmaceutical Inc.
• Jean-Paul Clozel, Actelion Pharmaceuticals, Ltd
• Colin Goddard, OSI
• Louis Lange, CV Therapeutics
45 The Darwinian challenge: why evolution is vital for
building biotech
Adelene Q. Perkins, Infinity Pharmaceuticals, Inc.
building biotech
Adelene Q. Perkins, Infinity Pharmaceuticals, Inc.
47 Connecting the dots: the impact of the global financial crisis
on biotechnology
on biotechnology
Peter Wirth, Genzyme Corporation
48 US financing
Collateral damage
Collateral damage
52 A closer look
State capital: incentive programs
State capital: incentive programs
53 US deals
Buying biotech, being biotech
Buying biotech, being biotech
56 A closer look
New rules for the M&A road
New rules for the M&A road
59 US public policy
Will biotech get the change it needs?
Will biotech get the change it needs?
60 A closer look
The FDA: transforming an agency in crisis
63 US products and technologies
Monitoring progress
Monitoring progress
66 Canada year in review
A time of reckoning
A time of reckoning
Staying afloat? The European perspective
European section
74 European introduction
Staying afloat?
77 Roundtable on deals
New deal structures for challenging times
• Naseem Amin, Biogen Idec
• Jeffrey Elton, Novartis Institutes for BioMedical Research
• John Goddard, AstraZeneca PLC
• Mervyn Turner, Merck & Co., Inc.
New deal structures for challenging times
• Naseem Amin, Biogen Idec
• Jeffrey Elton, Novartis Institutes for BioMedical Research
• John Goddard, AstraZeneca PLC
• Mervyn Turner, Merck & Co., Inc.
84 European financing
Down, but not out
Down, but not out
90 European deals
Dealing by dealing
Dealing by dealing
94 A closer look
Up-fronts and bottom lines: accounting for up-front payments under IFRS
Up-fronts and bottom lines: accounting for up-front payments under IFRS
95 European products and pipeline
A surging pipeline and a trickle of products
A surging pipeline and a trickle of products
98 A closer look
Growing pains in the European biosimilars market
Growing pains in the European biosimilars market
101 Roundtable on industrial biotechnology
Evolution, progress and sustainability
• Karl-Heinz Maurer, Henkel AG & Co. KGaA
• Marcel Wubbolts, DSM Innovation Center
• Holger Zinke, BRAIN AG
Evolution, progress and sustainability
• Karl-Heinz Maurer, Henkel AG & Co. KGaA
• Marcel Wubbolts, DSM Innovation Center
• Holger Zinke, BRAIN AG
Seeds of change? The Asia-Pacific perspective
Asia-Pacific section
106 Asia-Pacific introduction
Seeds of change?
Seeds of change?
107 The dream of the sea turtles: can China offer a new model for
Western biotech companies?
Samantha Du, Hutchison MediPharma Limited
Western biotech companies?
Samantha Du, Hutchison MediPharma Limited
108 Changing realities
A conversation with M.K. Bhan
110 Australia year in review
Haves and have-nots
Haves and have-nots
114 India year in review
Nurturing growth
Nurturing growth
115 A closer look
If you build it, will they come?
If you build it, will they come?
117 China year in review
On the road to innovation
120 Japan year in review
Seeking investors, seeking innovation
Seeking investors, seeking innovation
122 New Zealand year in review
Strong research and creative approaches
Strong research and creative approaches
122 A closer look
Attracting new investment: New Zealand’s new LP structure
Attracting new investment: New Zealand’s new LP structure
124 Singapore year in review
Looking beyond borders
Looking beyond borders
Resources
125 Acknowledgements
126 Data exhibit index
128 Global biotechnology contacts
☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.
관련정보
지식
동향
- 산업동향 2019 바이오경제 구축 보고서 제6호 2019-08-13
- 산업동향 Trends in White biotech 제48호 2013-06-21
- 제도동향 Emerging biotechnologies : technology, choice and the public good 2013-01-30
- 정책동향 What Europe has to offer biotechnology companies 2012-10-18
- 정책동향 Life Sciences Outlook 2012 Dutch biotech companies : from start-up to exit 2012-06-05